Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission

Shinya Tasaki, Katsuya Suzuki, Yoshiaki Kassai, Masaru Takeshita, Atsuko Murota, Yasushi Kondo, Tatsuya Ando, Yusuke Nakayama, Yuumi Okuzono, Maiko Takiguchi, Rina Kurisu, Takahiro Miyazaki, Keiko Yoshimoto, Hidekata Yasuoka, Kunihiro Yamaoka, Rimpei Morita, Akihiko Yoshimura, Hiroyoshi Toyoshiba, Tsutomu Takeuchi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Sustained clinical remission (CR) without drug treatment has not been achieved in patients with rheumatoid arthritis (RA). This implies a substantial difference between CR and the healthy state, but it has yet to be quantified. We report a longitudinal monitoring of the drug response at multi-omics levels in the peripheral blood of patients with RA. Our data reveal that drug treatments alter the molecular profile closer to that of HCs at the transcriptome, serum proteome, and immunophenotype level. Patient follow-up suggests that the molecular profile after drug treatments is associated with long-term stable CR. In addition, we identify molecular signatures that are resistant to drug treatments. These signatures are associated with RA independently of known disease severity indexes and are largely explained by the imbalance of neutrophils, monocytes, and lymphocytes. This high-dimensional phenotyping provides a quantitative measure of molecular remission and illustrates a multi-omics approach to understanding drug response.

Original languageEnglish
Article number2755
JournalNature Communications
Volume9
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Drug therapy
arthritis
Drug Monitoring
Rheumatoid Arthritis
drugs
Monitoring
Pharmaceutical Preparations
Lymphocytes
Proteome
proteome
signatures
monocytes
neutrophils
Therapeutics
Blood
Transcriptome
lymphocytes
Monocytes
profiles
Neutrophils

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. / Tasaki, Shinya; Suzuki, Katsuya; Kassai, Yoshiaki; Takeshita, Masaru; Murota, Atsuko; Kondo, Yasushi; Ando, Tatsuya; Nakayama, Yusuke; Okuzono, Yuumi; Takiguchi, Maiko; Kurisu, Rina; Miyazaki, Takahiro; Yoshimoto, Keiko; Yasuoka, Hidekata; Yamaoka, Kunihiro; Morita, Rimpei; Yoshimura, Akihiko; Toyoshiba, Hiroyoshi; Takeuchi, Tsutomu.

In: Nature Communications, Vol. 9, No. 1, 2755, 01.12.2018.

Research output: Contribution to journalArticle

Tasaki, S, Suzuki, K, Kassai, Y, Takeshita, M, Murota, A, Kondo, Y, Ando, T, Nakayama, Y, Okuzono, Y, Takiguchi, M, Kurisu, R, Miyazaki, T, Yoshimoto, K, Yasuoka, H, Yamaoka, K, Morita, R, Yoshimura, A, Toyoshiba, H & Takeuchi, T 2018, 'Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission', Nature Communications, vol. 9, no. 1, 2755. https://doi.org/10.1038/s41467-018-05044-4
Tasaki, Shinya ; Suzuki, Katsuya ; Kassai, Yoshiaki ; Takeshita, Masaru ; Murota, Atsuko ; Kondo, Yasushi ; Ando, Tatsuya ; Nakayama, Yusuke ; Okuzono, Yuumi ; Takiguchi, Maiko ; Kurisu, Rina ; Miyazaki, Takahiro ; Yoshimoto, Keiko ; Yasuoka, Hidekata ; Yamaoka, Kunihiro ; Morita, Rimpei ; Yoshimura, Akihiko ; Toyoshiba, Hiroyoshi ; Takeuchi, Tsutomu. / Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{5f05c4e14f16430ba1a2810fc7c6979c,
title = "Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission",
abstract = "Sustained clinical remission (CR) without drug treatment has not been achieved in patients with rheumatoid arthritis (RA). This implies a substantial difference between CR and the healthy state, but it has yet to be quantified. We report a longitudinal monitoring of the drug response at multi-omics levels in the peripheral blood of patients with RA. Our data reveal that drug treatments alter the molecular profile closer to that of HCs at the transcriptome, serum proteome, and immunophenotype level. Patient follow-up suggests that the molecular profile after drug treatments is associated with long-term stable CR. In addition, we identify molecular signatures that are resistant to drug treatments. These signatures are associated with RA independently of known disease severity indexes and are largely explained by the imbalance of neutrophils, monocytes, and lymphocytes. This high-dimensional phenotyping provides a quantitative measure of molecular remission and illustrates a multi-omics approach to understanding drug response.",
author = "Shinya Tasaki and Katsuya Suzuki and Yoshiaki Kassai and Masaru Takeshita and Atsuko Murota and Yasushi Kondo and Tatsuya Ando and Yusuke Nakayama and Yuumi Okuzono and Maiko Takiguchi and Rina Kurisu and Takahiro Miyazaki and Keiko Yoshimoto and Hidekata Yasuoka and Kunihiro Yamaoka and Rimpei Morita and Akihiko Yoshimura and Hiroyoshi Toyoshiba and Tsutomu Takeuchi",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-05044-4",
language = "English",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission

AU - Tasaki, Shinya

AU - Suzuki, Katsuya

AU - Kassai, Yoshiaki

AU - Takeshita, Masaru

AU - Murota, Atsuko

AU - Kondo, Yasushi

AU - Ando, Tatsuya

AU - Nakayama, Yusuke

AU - Okuzono, Yuumi

AU - Takiguchi, Maiko

AU - Kurisu, Rina

AU - Miyazaki, Takahiro

AU - Yoshimoto, Keiko

AU - Yasuoka, Hidekata

AU - Yamaoka, Kunihiro

AU - Morita, Rimpei

AU - Yoshimura, Akihiko

AU - Toyoshiba, Hiroyoshi

AU - Takeuchi, Tsutomu

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Sustained clinical remission (CR) without drug treatment has not been achieved in patients with rheumatoid arthritis (RA). This implies a substantial difference between CR and the healthy state, but it has yet to be quantified. We report a longitudinal monitoring of the drug response at multi-omics levels in the peripheral blood of patients with RA. Our data reveal that drug treatments alter the molecular profile closer to that of HCs at the transcriptome, serum proteome, and immunophenotype level. Patient follow-up suggests that the molecular profile after drug treatments is associated with long-term stable CR. In addition, we identify molecular signatures that are resistant to drug treatments. These signatures are associated with RA independently of known disease severity indexes and are largely explained by the imbalance of neutrophils, monocytes, and lymphocytes. This high-dimensional phenotyping provides a quantitative measure of molecular remission and illustrates a multi-omics approach to understanding drug response.

AB - Sustained clinical remission (CR) without drug treatment has not been achieved in patients with rheumatoid arthritis (RA). This implies a substantial difference between CR and the healthy state, but it has yet to be quantified. We report a longitudinal monitoring of the drug response at multi-omics levels in the peripheral blood of patients with RA. Our data reveal that drug treatments alter the molecular profile closer to that of HCs at the transcriptome, serum proteome, and immunophenotype level. Patient follow-up suggests that the molecular profile after drug treatments is associated with long-term stable CR. In addition, we identify molecular signatures that are resistant to drug treatments. These signatures are associated with RA independently of known disease severity indexes and are largely explained by the imbalance of neutrophils, monocytes, and lymphocytes. This high-dimensional phenotyping provides a quantitative measure of molecular remission and illustrates a multi-omics approach to understanding drug response.

UR - http://www.scopus.com/inward/record.url?scp=85050404860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050404860&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-05044-4

DO - 10.1038/s41467-018-05044-4

M3 - Article

C2 - 30013029

AN - SCOPUS:85050404860

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 2755

ER -